ICAM1 and cutaneous mastocytosis: When stratifying our study participants into distinct clinical categories to assess the potential inhibitory role of their antibodies, plasma from children with UM showed higher inhibition of PFD1235w DBLβ binding to ICAM-1 compared to plasma from SM children, including CM cases (Fig. 4).